A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 626 participants.
Also called NCT06131372
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 626 participants
- Sponsor
- Registry
-
NCT06131372 -
2023-505857-42
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Brazil, Canada, France, Greece, Hungary, India, Japan, Poland, Slovakia, Spain, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT06131372. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2025-09-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
- Condition
- Chronic Kidney Disease
- Condition
- Type 2 Diabetes
- Condition
- Obesity
- Intervention (Drug)
- Cagrilintide
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06131372- Content hash
8b8c610e26cc97bb04fd86505b2fe7be7f011495c559c0a04167174f47214b4e